重组人血管内皮抑制素联合XELOX方案治疗晚期结直肠癌患者的效果评价

目的:探讨重组人血管内皮抑制素联合卡培他滨+奥沙利铂(XELOX)方案治疗晚期结直肠癌患者的临床效果。方法:选取60例结直肠癌患者为研究对象,按随机数字表法分为观察组和对照组各30例。对照组予以XELOX方案治疗,观察组在对照组基础上予以重组人血管内皮抑制素治疗。比较两组患者的疾病控制率、不良反应发生率、无进展生存期及总生存期。结果:观察组疾病控制率为70.00%(21/30),与对照组的53.33%(16/30)比较,差异无统计学意义(P>0.05)。观察组不良反应发生率为16.67%(5/30),与对照组的13.33%(4/30)比较,差异无统计学意义(P>0.05)。观察组无进展生存期、总生存期均长于对照组,差异有统计学意义(P<0.05)。结论:重组人血管内皮抑制素联合XELOX方案应用于晚期结直肠癌患者中疾病控制效果确切,并可延长无进展生存期和总生存期,且未明显增高不良反应发生率。

Evaluation of effects of recombinant human endostatin combined with XELOX regimen on patients with advanced colorectal cancer

Objective:To analyze clinical effect of recombinant human endostatin plus Capecitabine plus Oxaliplatin(XELOX)regimen in treatment of advanced colorectal cancer.Methods:60 patients with colorectal cancer were selected as the research objects,and were divided into observation group(n=30)and control group(n=30)according to the random number table method.The control group was treated with XELOX regimen,while the observation group was treated with recombinant human endostatin on the basis of that of the control group.The disease control rate,incidence of adverse reactions,progression-free survival time,and overall survival time were compared between the two groups.Results:The disease control rates in the observation group and the control group were 70.00%(21/30)and 53.33%(16/30),respectively,and the difference was not statistically significant(P>0.05).There was no statistical difference in the incidence of adverse reactions between the observation group(16.67%,5/30)and the control group(13.33%,4/30)(P>0.05).However,there were statistical differences in the progression-free survival time and overall survival time between the two group(P<0.05).Conclusions:Recombinant human endostatin combined with XELOX regimen is effective in the patients with advanced colorectal cancer,and can extend the progression-free survival time and overall survival time without significantly increasing adverse reactions.